Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) – Equities research analysts at HC Wainwright issued their Q2 2023 earnings per share (EPS) estimates for Acer Therapeutics in a research report issued to clients and investors on Tuesday, March 28th. HC Wainwright analyst V. Bernardino forecasts that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Acer Therapeutics' current full-year earnings is ($0.23) per share.
Get Acer Therapeutics alerts:Acer Therapeutics Stock Up 1.3 %
Acer Therapeutics stock opened at $0.76 on Wednesday. Acer Therapeutics has a 52 week low of $0.65 and a 52 week high of $4.56. The company has a market capitalization of $16.01 million, a price-to-earnings ratio of -0.53 and a beta of 0.65. The stock has a 50-day moving average price of $1.86 and a 200 day moving average price of $1.84.
Institutional Trading of Acer Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its stake in shares of Acer Therapeutics by 76.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,226,191 shares of the biopharmaceutical company's stock worth $3,078,000 after acquiring an additional 529,653 shares during the last quarter. Knott David M Jr acquired a new stake in shares of Acer Therapeutics in the fourth quarter worth approximately $351,000. Vanguard Group Inc. boosted its stake in shares of Acer Therapeutics by 55.5% in the first quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company's stock worth $807,000 after acquiring an additional 99,335 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of Acer Therapeutics in the fourth quarter worth approximately $180,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Acer Therapeutics by 216.8% in the second quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company's stock worth $88,000 after acquiring an additional 47,700 shares during the last quarter. 27.96% of the stock is currently owned by hedge funds and other institutional investors.
About Acer Therapeutics
(Get Rating)
Acer Therapeutics, Inc is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases.
See Also
- Get a free copy of the StockNews.com research report on Acer Therapeutics (ACER)
- Dave & Buster's Rebound Could Score for Investors
- Cal-Maine: Is it Time to Chase this Stock Higher?
- The Most Important Warren Buffett Stock for Investors: His Own
- Three Mid Caps Wall Street Sees Doubling Within 12 Months
- It's No Stretch: Lululemon Could Break Out of its Range
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.